细化搜索
结果 1-2 的 2
Expression, purification, and bioactivity of a soluble recombinant ovine interferon-tau in Escherichia coli 全文
2021
Yu, Hai-Yang | Gao, Dong-Mei | Zhou, Wei | Xia, Bing-Bing | He, Zhi-Yuan | Wu, Bo | Jiang, Min-Zhi | Wang, Mingli | Zhao, Jun
Expression, purification, and bioactivity of a soluble recombinant ovine interferon-tau in Escherichia coli 全文
2021
Yu, Hai-Yang | Gao, Dong-Mei | Zhou, Wei | Xia, Bing-Bing | He, Zhi-Yuan | Wu, Bo | Jiang, Min-Zhi | Wang, Mingli | Zhao, Jun
Ovine interferon-tau (oIFN-τ) is a newly discovered type I interferon. This study used biochemical techniques to transform the oIFN-τ gene into Escherichia coli to obtain the mass and soluble expression of the recombinant protein. First, total RNA was extracted from fresh sheep embryonic tissues with TRIzol reagent and then used as a template to reverse transcribe and amplify the mature oIFN-τ gene with RT-PCR. The amplified product was next digested with the HindIII and XhoI restriction enzymes and inserted into the pET-32a(+) vector to construct the prokaryotic expression plasmid. The corrected in-frame recombinant plasmid, pET-32a(+)-oIFN-τ, was transformed into E. coli Rosetta (DE3) competent cells. After induction with isopropyl-beta-D-thiogalactopyranoside (IPTG), the recombinant protein was detected in bacteria. Finally, the bacteria were lysed by sonication, and the recombinant protein was purified by nickel affinity chromatography and DEAE anion exchange chromatography. The protein was confirmed to be oIFN-τ, which mainly existed in the soluble lysate fraction, as proven by SDS-PAGE and Western blot assays. Purified IFN-τ exists mostly in a soluble form, and its anti-vesicular stomatitis virus (VSV) activity reached 7.08×10(6)IU/mL.
显示更多 [+] 显示较少 [-]Expression, purification, and bioactivity of a soluble recombinant ovine interferon-tau in Escherichia coli 全文
2021
Yu Hai-Yang | Gao Dong-Mei | Zhou Wei | Xia Bing-Bing | He Zhi-Yuan | Wu Bo | Jiang Min-Zhi | Wang Ming-Li | Zhao Jun
Ovine interferon-tau (oIFN-τ) is a newly discovered type I interferon. This study used biochemical techniques to transform the oIFN-τ gene into Escherichia coli to obtain the mass and soluble expression of the recombinant protein.
显示更多 [+] 显示较少 [-]Transient and stable transfection of Chinese hamster ovary cells with the recombinant feline erythropoietin gene and expression, purification, and biological activity of feline erythropoietin protein 全文
2003
Baldwin, Susan L. | Powell, Tim D. | Wonderling, Ramani S. | Keiser, Katherine C. | Morales, Tony | Hunter, Shirley | McDermott, Martin | Radecki, Steven V. | Milhausen, Michael J.
Objective-To use transient and stable transfection of Chinese hamster ovary cells to clone the gene encoding feline erythropoietin (feEPO) protein, characterize the expressed protein, and assess its biological activity. Sample Population-Cultures of Chinese hamster ovary or TF-1 cells. Procedure-The gene encoding feEPO was cloned into a eukaryotic expression plasmid. Chinese hamster ovary cells were transiently or stably transfected with the plasmid. Expressed recombinant feEPO (rfeEPO) protein was purified from transiently transfected cells. The protein was characterized by use of SDS gel electrophoresis and western blot analysis. Biological activity was assessed by measuring thymidine incorporation by TF-1 erythroleukemic cells. Results-Purified rfeEPO from supernatants of transiently transfected cells was determined to be 34 to 40 kilodaltons (kd) by use of SDS gel electrophoresis, whereas the molecular weight predicted from the amino acid sequence was 21.5 kd. The banding pattern and high molecular weight suggested the protein was glycosylated. The rfeEPO proteins derived from transient or stable transfections subsequently were determined to be biologically active in vitro. Conclusions and Clinical Relevance-The gene encoding feEPO can be transfected into eukaryotic cells, and the expressed rfeEPO protein is biologically active in vitro. Cats with chronic renal failure often are anemic as a result of reduced expression of erythropoietin (EPO). Treatment with human-derived EPO stimulates RBCs in anemic cats; however, treatment is often limited by the development of antibodies directed against the recombinant human protein, which can then cross-react with endogenous feEPO. Recombinant feEPO may prove beneficial for use in cats with chronic renal failure.
显示更多 [+] 显示较少 [-]